Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Saved in:
| Title: | Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer. |
|---|---|
| Authors: | Gandhi S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Slomba RT; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Janes C; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.; Clinical Trials Office, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Fitzpatrick V; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Miller J; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Ioannou G; Department of Pathology, Mount Sinai School of Medicine, New York, New York, USA., Ozbey S; Department of Pathology, Mount Sinai School of Medicine, New York, New York, USA., De Souza I; Department of Pathology, Mount Sinai School of Medicine, New York, New York, USA., Roudko V; Department of Pathology, Mount Sinai School of Medicine, New York, New York, USA., Kumar P; Department of Radiology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Kalathil S; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Kokolus KM; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Wang J; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Cortes Gomez E; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Takabe K; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Edge S; Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Young J; Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Cappuccino H; Department of Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Opyrchal M; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA., O'Connor T; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Levine EG; Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Gnjatic S; Medicine - Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Kalinski P; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA pawel.kalinski@roswellpark.org.; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Nov 14; Vol. 12 (11). Date of Electronic Publication: 2024 Nov 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
